New US deal for Oncimmune on the back of mixed results

Oncimmune Holdings PLC (LON:ONC) has inked a new deal with US diagnostics firm Biodesix for its EarlyCDT lung cancer test. CEO Adam Hill tells Proactive London how significant the deal is and lays out his new three year strategic vision for the company, underlining a newly-implemented and strengthened cash position as well as an ability to drive growth through commercial collaborations.
The new deal will be worth up to US$28mln to Oncimmune over the next five years, with the agreement open for renewal for another five year period up to 2029.